Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis

ClinicalTrials.gov ID: NCT04015518

Public ClinicalTrials.gov record NCT04015518. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIb Dose-finding Study to Evaluate Safety and Efficacy of Different Subcutaneous Doses of BI 655130 in Patients With Moderate to Severe Palmoplantar Pustulosis (PPP)

Study identification

NCT ID
NCT04015518
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
152 participants

Conditions and interventions

Interventions

  • Spesolimab Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 30, 2019
Primary completion
Aug 5, 2020
Completion
Jul 27, 2021
Last update posted
Oct 15, 2025

2019 – 2021

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
14
Facility City State ZIP Site status
Total Skin and Beauty Dermatology Center, PC Birmingham Alabama 35205
Wallace Medical Group Beverly Hills California 90211
Therapeutics Clinical Research San Diego California 92123
Advanced Medical Research PC Sandy Springs Georgia 30328
Epiphany Dermatology of Kansas, LLC Overland Park Kansas 66215
University of Missouri Health System Columbia Missouri 65212
Washington University School of Medicine St Louis Missouri 63108
Skin Specialists, P.C. Omaha Nebraska 68144
The Psoriasis Treatment Center of Central New Jersey East Windsor New Jersey 08520
Paddington Testing Co., Inc. Philadelphia Pennsylvania 19103
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213
Menter Dermatology Research Institute Dallas Texas 75246
University of Utah Health Murray Utah 84107
Virginia Clinical Research, Inc. Norfolk Virginia 23502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 74 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04015518, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 15, 2025 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04015518 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →